REGENERX BIOPHARMACEUTICALS INC 4
4 · REGENERX BIOPHARMACEUTICALS INC · Filed Sep 20, 2013
Insider Transaction Report
Form 4
CAVAZZA PAOLO
10% Owner
Transactions
- Purchase
Convertible Promissory Note (right to buy)
2013-09-12$150000.00/sh(indirect: Indirect)Exercise: $0.06From: 2013-09-12→ Common Stock
Footnotes (2)
- [F1]On September 12, 2013, Sinaf S.A. ("Sinaf") purchased a $150,000 convertible promissory note (the "Note") from the issuer in a private placement. The Note and any accrued interest thereon are convertible at the option of the holder at any time prior to repayment of the Note into common stock at a conversion price of $0.06 per share. The Note is payable upon the written demand of the holder thereof at any time after September 10, 2018 (the "Maturity Date"). Interest accrues on the unpaid principal amount at a rate equal to 5% per annum but it is not due and payable until the written demand of the holder for payment on or after the Maturity Date. The current outstanding principal amount, if converted into common stock, would result in the issuance of 2,500,000 shares. The number of shares of common stock to be issued upon conversion will be fixed on the conversion date and reported on a Form 4 within two business days after conversion.
- [F2]This security is held directly by Sinaf, which is a direct wholly-owned subsidiary of Aptafin S.p.A. ("Aptafin"). Aptafin is owned by Paolo Cavazza and members of his family.